Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revelation BiosciencesREVB -0.88%28 EV-to-OCF is 0.68 as of Aug. 11, 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, Revelation Biosciences ranks worse than 76.67% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Revelation Biosciences's Enterprise Value is $-6.37 Mil.
Revelation Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-9.33 Mil. Therefore, Revelation Biosciences's EV-to-OCF for today is 0.68.
The historical rank and industry rank for Revelation Biosciences's EV-to-OCF or its related term are showing as below:
REVB'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.68 Med: 0 Max: 0.68
Current: 0.68
During the past 6 years, the highest EV-to-OCF of Revelation Biosciences was 0.68. The lowest was 0.68. And the median was .
REVB's EV-to-OCF is ranked worse than 76.67% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs REVB: 0.68
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Revelation Biosciences's PE Ratio (TTM) for today is calculated as:
Revelation Biosciences's share price for today is $1.12.
Revelation Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Revelation Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revelation Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revelation Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Revelation Biosciences's EV-to-OCF falls into.
Revelation Biosciences's current Enterprise Value is $-6.37 Mil.
Revelation Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences (REVB) has a EV-to-OCF of 0.68 as of Aug. 11, 2026. Over the past decade, Revelation Biosciences' EV-to-OCF has ranged from 0.68 to 0.68. According to the industry distribution chart, Revelation Biosciences ranks #1078 out of 1406 companies in the Biotechnology industry, placing it in the top 76.7%.
Is Revelation Biosciences' EV-to-OCF too high?
Revelation Biosciences' current EV-to-OCF is 0.68. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 0.68. Based on the distribution chart, Revelation Biosciences ranks #1078 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' EV-to-OCF compare to ELAB and ENSC?
According to the Biotechnology industry distribution chart, Revelation Biosciences ranks #1078 out of 1406 companies for EV-to-OCF. This places Revelation Biosciences in the lower half of its industry. Historically, Revelation Biosciences' own EV-to-OCF has ranged from 0.68 to 0.68 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Revelation Biosciences's current EV-to-OCF is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current EV-to-OCF of 0.68. The current EV-to-OCF is 0.68. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current EV-to-OCF is 0.68 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score
Get the complete analysis for REVB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVB has been successfully added to your 
